MaxCyte Director Executes Stock Options Sale

MaxCyte (MXCT) has released an update.

MaxCyte Inc., a leading cell-engineering company, reported that Stanley Erck, a Non-Executive Director, exercised options on 47,689 shares and sold them at prices ranging from $3.625 to $3.880 per share, which represented 7.94% of his holdings. The transactions were conducted in accordance with a pre-arranged trading plan and resulted in Erck holding 0.2% of the company’s issued stock capital plus additional options and restricted stock units.

For further insights into MXCT stock, check out TipRanks’ Stock Analysis page.